Insulin degludec: overview of a novel ultra long‐acting basal insulin
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
All the basal insulin products currently available have suboptimal pharmacokinetic ( PK ) properties, with none reliably providing a reproducible and peakless pharmacodynamic ( PD ) effect that endures over 24 h from once‐daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mechanism of protracted absorption involving the formation of a depot of soluble multihexamer chains after subcutaneous injection. PK / PD studies show that insulin degludec has a very long duration of action, with a half‐life exceeding 25 h. Once‐daily dosing produces a steady‐state profile characterized by a near‐constant effect, which varies little from injection to injection in a given patient. Clinically, insulin degludec has been shown consistently to carry a lower risk of nocturnal hypoglycaemia than once‐daily insulin glargine, in both basal+bolus and basal‐only insulin regimens. The constancy of the steady‐state profile of insulin degludec also means that day‐to‐day irregularities at the time of injection have relatively little PD influence, thereby offering the possibility of greater treatment flexibility for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citationHeise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447 · cited 1×
“This is less convenient, and is also less efficient since twice-daily dosing of a basal insulin tends to drive up dose consumption disproportionately to the gain in glycaemic control [15,16,18].”
BackgroundSelf-citationHeller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402 · cited 1×
“In a large-scale phase 3 study, patients with T1D were randomized to receive once-daily insulin degludec or glargine, again with mealtime insulin aspart [42].”
BackgroundHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 2×
“Notably, with once-daily dosing, degludec should produce a steady-state concentration with a low peak : trough ratio, which, coupled with low day-to-day variability, raises the expectation of a very low risk of hypoglycaemia [32].”
BackgroundInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 1×
“8 U/kg) were also investigated in the T2D study [27], and after 6 days of treatment the glucose-lowering effect of degludec was found to be evenly distributed between the first and second 12-h periods for all the three dose levels, reflecting the PK data (figure 3).”
MethodBolli, G. B., & Owens, D. R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02546-0 · Cited by 186
Cited by
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
“The time-action profile of insulin degludec at steady state with once-daily dosing is characterized by a near-constant plasma level with minimal peak to trough, reducing day-to-day variability (61).”
BackgroundInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
“basal analogue insulins whose PK profiles extend beyond 24 hours have been shown to have a stable steady-state profile, greater reproducibility and less day-to-day variability of action.(75) These properties”
BackgroundPharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
Metadata
- Authors
- Gough, S. C. L., Harris, S., Woo, V., & Davies, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-01-29
- Volume
- 15
- Issue
- 4
- Pages
- 301-309
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1974288288
- Cited by
- 74
- References
- 11
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin degludec: overview of a novel ultra long‐acting basal insulin. https://app.cochat.ai/papers/10.1111/dom.12052
- The paper
- Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013). Insulin degludec: overview of a novel ultra long‐acting basal insulin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.